Your browser is no longer supported. Please, upgrade your browser.
Settings
SNSS Sunesis Pharmaceuticals, Inc. daily Stock Chart
SNSS [NASD]
Sunesis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.94 Insider Own0.66% Shs Outstand23.29M Perf Week-8.68%
Market Cap51.47M Forward P/E- EPS next Y-1.39 Insider Trans0.00% Shs Float23.29M Perf Month2.79%
Income-36.20M PEG- EPS next Q-0.37 Inst Own68.50% Short Float1.20% Perf Quarter-13.67%
Sales2.00M P/S25.74 EPS this Y19.70% Inst Trans-0.10% Short Ratio2.43 Perf Half Y-39.78%
Book/sh-0.29 P/B- EPS next Y13.70% ROA-112.00% Target Price5.50 Perf Year-49.77%
Cash/sh0.97 P/C2.27 EPS next 5Y- ROE632.90% 52W Range1.84 - 4.53 Perf YTD-38.95%
Dividend- P/FCF- EPS past 5Y1.40% ROI-219.60% 52W High-51.21% Beta1.38
Dividend %- Quick Ratio3.40 Sales past 5Y-12.70% Gross Margin- 52W Low20.11% ATR0.16
Employees37 Current Ratio3.40 Sales Q/Q- Oper. Margin- RSI (14)53.30 Volatility7.55% 7.46%
OptionableYes Debt/Eq- EPS Q/Q43.00% Profit Margin- Rel Volume17.94 Prev Close2.22
ShortableYes LT Debt/Eq- EarningsNov 02 BMO Payout- Avg Volume114.87K Price2.21
Recom2.00 SMA204.96% SMA500.90% SMA200-30.56% Volume2,060,961 Change-0.45%
Jul-29-16Upgrade Wells Fargo Market Perform → Outperform
Jul-24-15Downgrade ROTH Capital Buy → Sell $5.50 → $1
Jul-24-15Downgrade Cantor Fitzgerald Buy → Hold
Jun-15-15Reiterated ROTH Capital Buy $4 → $5.50
May-05-15Reiterated ROTH Capital Buy $4.30 → $4
Dec-15-14Upgrade ROTH Capital Neutral → Buy $2.30 → $4.30
Dec-09-14Reiterated ROTH Capital Neutral $1.30 → $2.30
Oct-07-14Downgrade ROTH Capital Buy → Neutral $15 → $1.30
Oct-07-14Downgrade RBC Capital Mkts Outperform → Sector Perform $9 → $3
Jun-12-14Initiated UBS Buy $14
Sep-11-12Reiterated Cantor Fitzgerald Buy $6 → $8
May-29-12Upgrade RBC Capital Mkts Sector Perform → Outperform $3 → $5
Apr-13-12Initiated Cantor Fitzgerald Buy $6
Mar-06-12Initiated Canaccord Genuity Buy $4
Oct-11-11Downgrade RBC Capital Mkts Outperform → Sector Perform $4 → $3
Sep-29-11Initiated MLV Capital Buy $3.50
Oct-03-17 09:36AM  Zacks.com featured highlights include MINDBODY, TearLab, Sunesis Pharmaceuticals, Children's Place, Franklin Electric Zacks
Oct-02-17 06:21AM  Step Beyond Bargain Hunting: 5 Stocks With Rising P/E Zacks
Aug-31-17 07:00AM  Sunesis to Present at Upcoming Investor Conferences GlobeNewswire
Aug-13-17 09:25AM  Edited Transcript of SNSS earnings conference call or presentation 27-Jul-17 6:00pm GMT Thomson Reuters StreetEvents
Jul-27-17 02:53PM  Sunesis reports 2Q loss Associated Press
07:00AM  Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Jul-24-17 07:00AM  Sunesis to Host Conference Call on July 27th to Discuss Second Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Jul-18-17 04:05PM  Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies GlobeNewswire
Jun-26-17 07:00AM  Sunesis Pharmaceuticals Added to Russell Microcap® Index GlobeNewswire
Jun-23-17 07:00AM  Sunesis Pharmaceuticals Announces Presentation of Updated Results from Washington University-Sponsored Phase 1/Cohort Expansion Trial of Vosaroxin Plus Azacitidine in Patients with MDS at the EHA Annual Meeting GlobeNewswire +7.41%
May-19-17 06:18PM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm Business Wire
08:45AM  The Life Sciences Report Examines How Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug Marketwired
May-15-17 07:08PM  Lifshitz & Miller LLP Announces Investigation of Anadarko Petroleum Corporation, DryShips Inc., ImmunoCellular Therapeutics, Ltd., KBR, Inc., Sunesis Pharmaceuticals, Inc., Sunrun Inc. and Vince Holding Corp. PR Newswire
May-12-17 11:05PM  Edited Transcript of SNSS earnings conference call or presentation 8-May-17 6:00pm GMT Thomson Reuters StreetEvents
May-11-17 05:32PM  ETFs with exposure to Sunesis Pharmaceuticals, Inc. : May 11, 2017 Capital Cube
May-10-17 10:25AM  Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 Capital Cube
May-08-17 09:00AM  Investor Network: Sunesis Pharmaceuticals, Inc. to Host Earnings Call Accesswire
07:04AM  Sunesis reports 1Q loss Associated Press
07:00AM  Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
May-04-17 02:49PM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
May-03-17 06:47PM  INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sunesis Pharmaceuticals, Inc. Investors Business Wire
01:27PM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm Business Wire
11:54AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Sunesis Pharmaceuticals Inc. Business Wire
08:15AM  Blog Coverage Sunesis Pharma Withdraws European Marketing Authorization Application for Vosaroxin Accesswire
May-02-17 08:44PM  INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. Business Wire -18.99%
08:39PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sunesis Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
06:38PM  SUNESIS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Sunesis Pharmaceuticals Inc. To Contact The Firm PR Newswire
03:47PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sunesis Pharmaceuticals, Inc. - SNSS PR Newswire
03:21PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sunesis Pharmaceuticals, Inc. (SNSS) PR Newswire
May-01-17 05:47PM  Sunesis shares drop as biotech drops leukemia drug marketing application MarketWatch -5.43%
04:30PM  Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML GlobeNewswire
Apr-03-17 08:00AM  Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting GlobeNewswire
Mar-28-17 07:00AM  Sunesis Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-27-17 04:35PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
Mar-22-17 07:00AM  Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin GlobeNewswire
Mar-20-17 08:33AM  Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
08:33AM  Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
Mar-15-17 01:04PM  SUNESIS PHARMACEUTICALS INC Financials
Mar-14-17 02:42PM  Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube
02:42PM  Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-10-17 02:19PM  Edited Transcript of SNSS earnings conference call or presentation 9-Mar-17 4:00pm GMT Thomson Reuters StreetEvents
Mar-09-17 11:00AM  Sunesis Pharmaceuticals Inc Earnings Call scheduled for 11:00 am ET today
09:31AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
09:15AM  Spectrum (SPPI) Q4 Loss Narrower than Expected, Sales Beat
07:20AM  Sunesis reports 4Q loss Associated Press
07:07AM  Q4 2016 Sunesis Pharmaceuticals Inc Earnings Release - Before Market Open
07:00AM  Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights GlobeNewswire
Mar-08-17 04:55PM  Seattle Genetics (SGEN): FDA Lifts Hold on Trial of AML Drug Zacks
Mar-07-17 04:08PM  GlaxoSmithKline's Nucala Positive in Label Expansion Study
Mar-03-17 09:32AM  Nektar Therapeutics (NKTR) Loss Wider than Expected in Q4
Mar-02-17 05:08PM  Merrimack (MACK) Q4 Loss Lower than Expected, Revenues Top
07:00AM  Sunesis to Host Conference Call on March 9th to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights GlobeNewswire
Mar-01-17 04:46PM  Valeant (VRX) Tops Q4 Earnings, Shares Down on Tepid View
07:00AM  Sunesis Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Feb-28-17 12:17PM  Endo (ENDP) Beats on Q4 Earnings, Revenues; Guides Low
12:15PM  Horizon (HZNP) Misses on Earnings in Q4, View Disappoints
11:46AM  Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y
Feb-27-17 08:23AM  Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss
Feb-24-17 03:25PM  Emergent (EBS) Beats Earnings, Revenue Estimates in Q4
Feb-23-17 09:58AM  Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line
Feb-22-17 05:08PM  Pfizer's Leukemia Candidate Gets Priority Review in U.S.
Feb-20-17 09:06AM  ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y
Feb-17-17 02:04PM  Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View
09:27AM  Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up
Feb-16-17 04:19PM  Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y
Feb-15-17 02:36PM  Prothena (PRTA) Reports Wider-than-Expected Loss in Q4
10:08AM  AMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates
Feb-10-17 02:15PM  Seattle Genetics (SGEN) Loss Wider than Expected in Q4, Revenues Miss
Feb-08-17 09:30AM  The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals
Feb-07-17 03:26PM  5 Great Biotech Stocks to Buy Now
10:56AM  Mallinckrodt (MNK) Tops on Earnings in Transition Quarter
Feb-06-17 07:00AM  Sunesis Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference GlobeNewswire
Feb-02-17 09:49AM  Novartis (NVS) Votubia Gets EU Approval for Label Expansion
Jan-31-17 05:40PM  Endo's (ENDP) Ephedrine Sulfate Injection Gets FDA Approval
10:46AM  Eli Lilly (LLY) Misses on Q4 Earnings, Beats on Revenues
Jan-30-17 05:27PM  Novo Nordisk Inks Diabetes Deal with University of Oxford
04:19PM  Endo (ENDP) Restructures Branded Pharmaceutical Unit (revised)
10:20AM  Celgene (CELG) Gets Favorable CHMP Opinion for Revlimid
08:00AM  Protalix BioTherapeutics (PLX) Jumps: Stock Rises by 11.7%
Jan-27-17 05:36PM  AstraZeneca's Symbicort Granted Pediatric Exclusivity by FDA
05:10PM  Immunogen Doses First Patient in Ovarian Cancer Drug Study
09:05AM  Endo (ENDP) Restructures its Branded Pharmaceutical Unit
08:53AM  J&J to Acquire Actelion for $30B: Is It a Strategic Fit?
Jan-26-17 03:29PM  Celgene (CELG) Misses on Earnings & Revenues, Keeps View
Jan-25-17 05:30PM  Roche (RHHBY) Arthritis Drug Actemra sBLA Accepted by FDA
08:45AM  Novartis (NVS) Beats Q4 Earnings, Might Spin-Off Alcon
Jan-24-17 04:06PM  Sunesis Offers Updates on SNS-062 and Qinprezo Programs
09:50AM  Endo (ENDP) Settles Disputes with Federal Trade Commission
09:21AM  Eagle Pharmaceuticals Wraps Up Ryanodex NDA Submission
08:20AM  Marinus Releases Positive Preliminary Data from CDKL5 Study
Jan-23-17 10:20AM  Minerva Presents Additional Data from Schizophrenia Drug
07:00AM  Sunesis Pharmaceuticals Announces Clinical and Regulatory Updates to SNS-062 and Vosaroxin Programs GlobeNewswire
Jan-20-17 08:39AM  Aduro (ADRO) Inks License Agreement with Stanford University
08:38AM  Synergy (SGYP) Trulance Wins FDA Approval for Constipation
Jan-18-17 08:28AM  Kura Oncology Starts Dosing Patients in Phase II CMML Study
Dec-15-16 07:57PM  How MEI Pharma Inc (MEIP) Stacks Up Against Its Peers at Insider Monkey
Dec-05-16 05:45PM  Sunesis Pharmaceuticals Announces Presentation of Updated Results from the VALOR Trial Examining Overall Survival in Patients Age 60 Years and Older with Relapsed/Refractory AML at the ASH Annual Meeting GlobeNewswire
07:00AM  Sunesis Pharmaceuticals Announces Presentation of Results from Completed Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK inhibitor SNS-062 at ASH Annual Meeting GlobeNewswire
Nov-03-16 11:10AM  Sunesis reports 3Q loss
11:00AM  Sunesis Pharmaceuticals Inc Earnings Call scheduled for 11:00 am ET today
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome; and developing SNS-062, a non-covalently binding inhibitor of the human protein Bruton's tyrosine kinase (BTK). The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parker Geoffrey M.DirectorDec 09Buy3.905942,31865,745Dec 12 06:43 PM
Parker Geoffrey M.DirectorDec 08Buy3.873,14612,15965,151Dec 12 06:43 PM